Michael McGarrity: Well, no, I would say that our inside expectations and model are coming along very much in line with our expectations. So we believe that, from a market perspective and transparency perspective, that we see upside to the original guidance we gave. And a lot of that is just based on seeing quarter-after-quarter continued execution. And then when we go deeper into that execution and look customer by customer, the sustainability, the adoption and the commitment to our pathway, that will continue to inform our view of our revenue growth. So we’re very confident, as you can imagine, in the $83 million to $85 million. And we’ll just continue to update on a quarterly basis.
Daniel Brennan: Got it. And I know there’s been a bunch of questions trying to tease out some of the contributions in the quarter, but any help on Resolve in the quarter? Since that’s a little bit different than your — than the prostate portfolio. Just wondering, how is Resolve doing? Is that still being a material contributor?
Michael McGarrity: It’s still a material contributor. The growth rate is continuing to be sustained, and we see continued adoption from our urology customer base of that test. So we view that as — we view our entire menu, that’s why I’m careful here. Individually and collectively, we’re seeing strength across the menu. And obviously, the Resolve fit within our customer base has been validated. So while we won’t grow 100% quarter-by-quarter sequentially as that business is built, we do see sustainable growth with that offering.
Daniel Brennan: Got it. And then like consensus was at $18 million, you obviously came in around $2 million above that. And the guidance raise at the midpoint is $4 million. So I’m just wondering, versus your prior view, have you raised what you guys expected Q2 to Q4 to be? Or are you just kind of booking the 1Q upside that you saw?
Michael McGarrity: Yes. I guess, Dan, I’m not going to share our modeling exercise internally, but I would say that we as a team and our Board has a view of expectations that is probably higher than what’s in the market. But we believe that our guidance reflects the confidence in our business and our clear visibility into our growth being sustainable. And that’s why I point to 3% growth in Q1. But I lean on the 20% growth. So I don’t want to overplay my Stryker experience, but that’s the way we think is that, if you have the right team and the right menu, the right focus and the right execution, the 20% top line growth should be our goal forever. So at least that’s our goal for the next few quarters.
Daniel Brennan: And then maybe last one, I know there’s been several questions on the germline test, and I apologize if you answered this, Mike. But did you give a price point on that test? Is it reimbursed today? And just anything on like sizing the addressable opportunity for that new germline test.
Michael McGarrity: Yes, Dan. So the addressable opportunity is I think the data would suggest that 10% to 20% of patients have hereditary risk. And so we view it as a real tool. It’s kind of driven, that’s why I made the analogy to women’s health and breast cancer. As awareness becomes more clear and men become more aware of the risks and the importance of the diagnostic availability for prostate cancer, it’s starting to look more like that. And we think the germline, whether it’s driven by the patient or once they present, it’s really meaningful information. And it can be prior to elevated PSA, post elevated PSA, post initial biopsy, so we like the fit there. And that was part of the diligence that we went through. And as far as the pricing, the Medicare rate for that test is $1,800.
Operator: Our next question is from the line of Thomas Vranken from KBC.
Thomas Vranken: Congrats on another quarter with solid progress as well as the upgrade of the guidance. Two questions from my side. I think the first one, it is also on the germline testing. So I understood, based on the news, that, that could start contributing to revenues as of Q2. Could you give an indication as to when you would expect the test to be accretive to margins as well? Is this going to be immediately? Or will this take some time?
